MedTrace Logo

Montelukast With Status Asthmaticus, Ages 2-5

NCT00491790 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2008-12-16

No results posted yet for this study

Summary

The purpose of this study is to determine if montelukast, in addition to standard treatment is helpful in treating patients ages 2-5 who are in the hospital because of status asthmaticus.

Conditions

Interventions

DRUG

Montelukast

Montelukast 4 mg rapid dissolving granules in sterile water given orally once

OTHER

Sterile water

Sterile water

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    lead NIH

  • Pediatric Pharmacology Research Units Network

    collaborator NETWORK

Principal Investigators

  • Jeffrey L. Blumer, M.D., Ph.D. · PPRU

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2010-01-31
Completion
2010-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00491790 on ClinicalTrials.gov